OBJECTIVE: To determine some of the mechanisms involved in insulin resistance immediately following burn trauma, and to determine the efficacy of PPAR-alpha agonism for alleviating insulin resistance in this population. SUMMARY BACKGROUND DATA: Hyperglycemia following trauma, especially burns, is well documented. However, the underlying insulin resistance is not well understood, and there are limited treatment options. METHODS:Twenty-one children 4 to 16 years of age with >40% total body surface area burns were enrolled in a double-blind, prospective, placebo-controlled randomized trial. Whole body and liver insulin sensitivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondrial function were measured in muscle biopsies taken before and after approximately 2 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3 weeks of injury. RESULTS: The change in average daily glucose concentrations was significant between groups after treatment (146 +/- 9 vs. 161 +/- 9 mg/dL PLA and 158 +/- 7 vs. 145 +/- 4 FEN; pretreatment vs. posttreatment; P = 0.004). Insulin-stimulated glucose uptake increased significantly in FEN (4.3 +/- 0.6 vs. 4.5 +/- 0.7 PLA and 5.2 +/- 0.5 vs. 7.6 +/- 0.6 mg/kg per minute FEN; pretreatment vs. posttreatment; P = 0.003). Insulin trended to suppress hepatic glucose release following fenofibrate treatment (P = 0.06). Maximal mitochondrial ATP production from pyruvate increased significantly after fenofibrate (P = 0.001) and was accompanied by maintained levels of cytochrome C oxidase and citrate synthase activity levels. Tyrosine phosphorylation of the insulin receptor and insulin receptor substrate-1 in response to insulin increased significantly following fenofibrate treatment (P = 0.04 for both). CONCLUSIONS: Fenofibrate treatment started within 1 week postburn and continued for 2 weeks significantly decreased plasma glucose concentrations by improving insulin sensitivity, insulin signaling, and mitochondrial glucose oxidation. Fenofibrate may be a potential new therapeutic option for treating insulin resistance following severe burn injury.
RCT Entities:
OBJECTIVE: To determine some of the mechanisms involved in insulin resistance immediately following burn trauma, and to determine the efficacy of PPAR-alpha agonism for alleviating insulin resistance in this population. SUMMARY BACKGROUND DATA: Hyperglycemia following trauma, especially burns, is well documented. However, the underlying insulin resistance is not well understood, and there are limited treatment options. METHODS: Twenty-one children 4 to 16 years of age with >40% total body surface area burns were enrolled in a double-blind, prospective, placebo-controlled randomized trial. Whole body and liver insulin sensitivity were assessed with a hyperinsulinemic-euglycemic clamp, and insulin signaling and mitochondrial function were measured in muscle biopsies taken before and after approximately 2 weeks of either placebo (PLA) or 5 mg/kg of PPAR-alpha agonist fenofibrate (FEN) treatment, within 3 weeks of injury. RESULTS: The change in average daily glucose concentrations was significant between groups after treatment (146 +/- 9 vs. 161 +/- 9 mg/dL PLA and 158 +/- 7 vs. 145 +/- 4 FEN; pretreatment vs. posttreatment; P = 0.004). Insulin-stimulated glucose uptake increased significantly in FEN (4.3 +/- 0.6 vs. 4.5 +/- 0.7 PLA and 5.2 +/- 0.5 vs. 7.6 +/- 0.6 mg/kg per minute FEN; pretreatment vs. posttreatment; P = 0.003). Insulin trended to suppress hepatic glucose release following fenofibrate treatment (P = 0.06). Maximal mitochondrial ATP production from pyruvate increased significantly after fenofibrate (P = 0.001) and was accompanied by maintained levels of cytochrome C oxidase and citrate synthase activity levels. Tyrosine phosphorylation of the insulin receptor and insulin receptor substrate-1 in response to insulin increased significantly following fenofibrate treatment (P = 0.04 for both). CONCLUSIONS:Fenofibrate treatment started within 1 week postburn and continued for 2 weeks significantly decreased plasma glucose concentrations by improving insulin sensitivity, insulin signaling, and mitochondrial glucose oxidation. Fenofibrate may be a potential new therapeutic option for treating insulin resistance following severe burn injury.
Authors: B Morio; J F Hocquette; C Montaurier; Y Boirie; C Bouteloup-Demange; C McCormack; N Fellmann; B Beaufrère; P Ritz Journal: Am J Physiol Endocrinol Metab Date: 2001-01 Impact factor: 4.310
Authors: Melanie G Cree; Jennifer J Zwetsloot; David N Herndon; Bradley R Newcomer; Ricki Y Fram; Carlos Angel; Justin M Green; Gerald L Dohm; Dayoung Sun; Asle Aarsland; Robert R Wolfe Journal: J Burn Care Res Date: 2008 Jul-Aug Impact factor: 1.845
Authors: Baiyu Zhou; Weihong Xu; David Herndon; Ronald Tompkins; Ronald Davis; Wenzhong Xiao; Wing Hung Wong; Mehmet Toner; H Shaw Warren; David A Schoenfeld; Laurence Rahme; Grace P McDonald-Smith; Douglas Hayden; Philip Mason; Shawn Fagan; Yong-Ming Yu; J Perren Cobb; Daniel G Remick; John A Mannick; James A Lederer; Richard L Gamelli; Geoffrey M Silver; Michael A West; Michael B Shapiro; Richard Smith; David G Camp; Weijun Qian; John Storey; Michael Mindrinos; Rob Tibshirani; Stephen Lowry; Steven Calvano; Irshad Chaudry; Michael A West; Mitchell Cohen; Ernest E Moore; Jeffrey Johnson; Lyle L Moldawer; Henry V Baker; Philip A Efron; Ulysses G J Balis; Timothy R Billiar; Juan B Ochoa; Jason L Sperry; Carol L Miller-Graziano; Asit K De; Paul E Bankey; Celeste C Finnerty; Marc G Jeschke; Joseph P Minei; Brett D Arnoldo; John L Hunt; Jureta Horton; J Perren Cobb; Bernard Brownstein; Bradley Freeman; Ronald V Maier; Avery B Nathens; Joseph Cuschieri; Nicole Gibran; Matthew Klein; Grant O'Keefe Journal: Proc Natl Acad Sci U S A Date: 2010-05-17 Impact factor: 11.205
Authors: Gerd G Gauglitz; Stefanie Halder; Darren F Boehning; Gabriela A Kulp; David N Herndon; José M Barral; Marc G Jeschke Journal: Shock Date: 2010-03 Impact factor: 3.454
Authors: Michael M Chen; Stewart R Carter; Brenda J Curtis; Eileen B O'Halloran; Richard L Gamelli; Elizabeth J Kovacs Journal: J Burn Care Res Date: 2017 Jan/Feb Impact factor: 1.845